PHIA Koninklijke Philips N.V.

Philips expands digital pathology portfolio with cloud-enabled Philips IntelliSite Pathology Solution on HealthSuite

Philips expands digital pathology portfolio with cloud-enabled Philips IntelliSite Pathology Solution on HealthSuite

March 11, 2026

Fully cloudenabled solution designed to help healthcare organizations scale digital pathology adoption and workflows

Amsterdam, The Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the expansion of its digital pathology portfolio with new cloud-enabled capabilities designed to help healthcare organizations scale digital diagnostics, improve productivity, and advance their transformation to fully digital workflows.

Philips IntelliSite Pathology Solution on HealthSuite¹, powered by Amazon Web Services (AWS) is a fully cloud-enabled digital pathology solution that helps pathology laboratories adopt and scale digital workflows without the complexity of on-premise infrastructure. The platform helps to securely store, manage, and enable analysis of large volumes of high-resolution pathology images while allowing pathologists to access, review, and collaborate on cases from virtually anywhere.2 By simplifying IT management and operations and supporting scalable data management and collaboration, the solution helps laboratories improve workflow efficiency and advance routine clinical use of digital pathology.



The cloud-enabled offering combines Philips’ leadership in digital pathology with AWS’ leading healthcare cloud infrastructure. In January 2026, recognized Philips with the 2025 Global Enabling Technology Leadership Award in Digital Pathology, while AWS was named 2026 Best in KLAS for Public Cloud Infrastructure.



Advancing digital pathology toward routine clinical practice

Healthcare organizations are under growing pressure to manage rising image volumes, address workforce shortages, and prepare for AI-enabled diagnostics. According to the , many pathology departments have yet to adopt digital pathology for routine clinical diagnosis and continue to operate hybrid environments where microscopes remain central to primary diagnosis.



Fully digital workflows can improve efficiency, enable collaboration and case review, enhance diagnostic consistency, and create structured data foundations that support quality improvement and scalable AI interoperability3. Philips’ cloud‑enabled digital pathology offering supports secure, remote access to images, simplifies data management at scale2, while supporting enterprise integration4 and AI‑enabled applications across health systems.



“As early adopters of digital pathology, we have already experienced the operational and clinical value of working in a fully digital environment,” said Dr. Cordon-Cardo, Chair of the Department of Pathology, Molecular and Cell-Based Medicine at Mount Sinai Health System. “As our program matures, the ability to scale efficiently across sites and manage the growing volume of pathology data becomes increasingly important. A cloud‑enabled deployment reduces reliance on on‑premise infrastructure while providing the flexibility, performance, and scalability required for enterprise collaboration and AI integration. This represents an important next step in advancing our digital pathology strategy."



A proven foundation for digital pathology

Philips’ includes whole‑slide , an , archive services, and implementation and support services that help laboratories transition from analog to digital pathology workflows. With thousands of digital pathology users worldwide and a growing number of clinical sites going fully digital, Philips has built one of the largest installed bases.

“By combining scalable cloud innovation with deep domain expertise and end-to-end services, we partner with our customers throughout their transformation journey – from the first digital slide to fully connected ecosystems that help turn data into actionable insight for precision care,” said Martijn Hartjes, Business Leader Clinical Informatics at Philips. “Successful digital pathology adoption is not about technology alone, it’s about reimagining how care teams access clinical data and collaborate across a health system.”

Expanding the Philips HealthSuite Integrated Diagnostics portfolio

Philips IntelliSite Pathology on HealthSuite is the newest addition to the – a rich suite of cloud-based diagnostic solutions, powered by AWS, and designed to connect data, integrate workflows, and embed AI across the diagnostic enterprise.4

The portfolio brings together Philips’ latest cloud innovations, architected to operate independently or connect across diagnostic domains.2 Other key solutions include Image Management on HealthSuite featuring Web Diagnostic Viewer, Cardiovascular Workspace on HealthSuite, and advanced visualization and AI management capabilities. Together, these solutions help health systems enable data interoperability 4, across radiology, cardiology, and pathology, streamline diagnostic workflows, and support more coordinated, data-driven care.

Philips will showcase its expanded digital pathology portfolio at (Las Vegas, March 9–12) and at (San Antonio, March 21–26).

1 PIPS on HealthSuite is work in progress and not available in the USA or any other jurisdiction. Future availability cannot be ensured.

2 Third party claims from AWS, which may not apply in all markets and may be updated from time to time. The functionalities and benefits of the solution depend on customer-specific configuration and use. Please contact your local Philips representative for (market) availability.

3 AI interoperability with PIPS on HealthSuite is a work in progress, is not available in the United States or any other jurisdiction, and will initially be available only with Ibex AI. Future availability cannot be guaranteed. Ibex AI and the contextual launch of Ibex AI within PIPS are Research Use Only (RUO) in the United States.

4 Not intended for diagnostic, monitoring or therapeutic purposes or in any other manner for regular medical practice.

For further information, please contact:

Anna Hogrebe

Philips Global External Relations

Tel.:

E-mail:  

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.



Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachment



EN
11/03/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

FDA clears Philips AI solution that provides real-time guidance during...

FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair March 26, 2026 Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures, supporting treatment [2]DeviceGuide integrates with Philips Azurion image-guided therapy platform that combines imaging, real-time data and intelligent software within a unified workflow to support more consistent, efficient and confidently guided minimally invasive procedures Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA...

 PRESS RELEASE

Philips launches IntraSight Plus to simplify coronary interventions an...

Philips launches IntraSight Plus to simplify coronary interventions and advance precision care March 25, 2026 Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient careWith FDA clearance and CE marking, IntraSight Plus streamlines the workflow efficiency of minimally invasive coronary procedures and can enable system operation time savings up to 47% in both the USA and Europe Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technolog...

 PRESS RELEASE

Philips remains No. 1 in Medtech at European Patent Office and the lar...

Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant March 24, 2026 Philips ranks No. 1 among medical technology companies in the European Patent Office Technology Dashboard 2025, filing 1,289 patent applications with the EPO in 2025.Philips’ platform-based solutions integrate hardware, software, data and AI to address clinical, operational and everyday health challenges.Philips’ innovation improved the lives of 2 billion people in 2025, with the goal of improving 2.5 billion lives per year by 2030, including 400 million people in medically unde...

 PRESS RELEASE

Philips convenes the Annual General Meeting of Shareholders 2026

Philips convenes the Annual General Meeting of Shareholders 2026 March 23, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. As previously announced, the agenda includes: Proposal to appoint John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.Proposals to re-appoint Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as m...

 PRESS RELEASE

Philips proposes new appointment and re-appointments to its Supervisor...

Philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment March 23, 2026 John DeFord proposed as new member of the Supervisory Board.Paul Stoffels, Herna Verhagen and Sanjay Poonen proposed for re-appointment as members of the Supervisory Board.Marc Harrison will step down from Philips’ Supervisory Board after his second term.Roy Jakobs proposed for re-appointment as President/CEO and Chairman and member of the Board of Management, as previously announced. Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology,...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch